Evidence map›Paper›PMID 37084852›Full record

Trial reportGastroenterology2023

Effects of FGF19 Analogue Aldafermin in Patients With Bile Acid Diarrhea: A Randomized, Placebo-Control Trial.

Joelle BouSaba, Monique Torres, Saam Dilmaghani, W Scott Harmsen, Lei Ling, Michael Camilleri

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. FGF-based drug discovery: advances and challenges.Nature reviews. Drug discovery · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Exploring endocrine FGFs - structures, functions and biomedical applications.International journal of biochemistry and molecular biology · 2024
    Review
  8. New Developments in Bile Acid Diarrhea.Gastroenterology & hepatology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joelle BouSabaClinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota.
Monique TorresClinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota.
Saam DilmaghaniClinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota.
W Scott HarmsenClinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota.
Lei LingNGM Biopharmaceuticals, South San Francisco, California.
Michael CamilleriClinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota. Electronic address: camilleri.michael@mayo.edu.

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Genetic Control and Ileo-Colonic Mucosal Expression of Bile Acid-Related Mechanisms in Irritable Bowel Syndrome-DiarrheaR01DK115950 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L. · 2018 to 2021
$1.8M
NCATS NIH HHS UL1 TR002377NIDDK NIH HHS R01 DK115950
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bile Acids and SaltsDiarrheaFibroblast Growth FactorsHumansaldaferminBile Acids and SaltsFGF19 protein, humanFibroblast Growth Factors

Identifiers

PMID37084852
PMCPMC10524746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.